Precise In Vivo Inflammation Imaging Using In Situ Responsive Cross‐linking of Glutathione‐Modified Ultra‐Small NIR‐II Lanthanide Nanoparticles | Zendy

Zhao Mengyao | Zendy; Wang Rui | Zendy; Li Benhao | Zendy; Fan Yong | Zendy; Wu Yifan | Zendy; Zhu Xinyan | Zendy; Zhang Fan | Zendy

Premium

Precise In Vivo Inflammation Imaging Using In Situ Responsive Cross‐linking of Glutathione‐Modified Ultra‐Small NIR‐II Lanthanide Nanoparticles

Author(s) -

Zhao Mengyao,

Wang Rui,

Li Benhao,

Fan Yong,

Wu Yifan,

Zhu Xinyan,

Zhang Fan

Publication year - 2019

Publication title -

angewandte chemie international edition

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 5.831

H-Index - 550

eISSN - 1521-3773

pISSN - 1433-7851

DOI - 10.1002/anie.201812878

Subject(s) - in vivo , glutathione , in situ , lanthanide , reactive oxygen species , nanoparticle , materials science , preclinical imaging , near infrared spectroscopy , biophysics , nanotechnology , chemistry , biochemistry , optics , enzyme , ion , microbiology and biotechnology , organic chemistry , biology , physics

To improve the bioimaging signal‐to‐noise ratio (SNR), long‐term imaging capability, and decrease the potential biotoxicity, an in vivo cross‐linking strategy was developed by using sub‐10 nm, glutathione‐modified, lanthanide nanoprobes. After administration, the nanoprobes cross‐link in response to reactive oxygen species (ROS) at the inflamed area and enable the quick imaging of ROS in the second near‐infrared (NIR‐II) window. These nanoprobes could be rapidly excreted due to their ultra‐small size. This strategy may also be applied to other ultra‐small contrast agents for the precise bioimaging by in situ lesion cross‐linking.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research